Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Scientists use hydrocarbon peptide stapling to develop cell permeable and stabile peptides capable of blocking RAB25-FIP complex formation. These peptides inhibit RAB25-depenent (pro- and anti-tumorigenic) phenotypes in cancer cells.
The CTD2 Dashboard is an interactive web interface which compiles conclusions with associated supporting evidence. This open access resource makes the data findable, accessible, interoperable and reusable to both computational and non-computational experts.
CTD2 scientists developed an Onco-GPS tool—a data-driven approach useful in establishing relationships—to explore cancers with altered RAS/MAPK. These components help to map individual samples onto a novel visual paradigm and strategize therapy against cancers with well-defined oncogenic lesions.
TARGET researchers performed comprehensive analysis of Wilms Tumors and identified convergence of numerous genetic changes on limited developmental pathways resulting in oncogenesis. Findings suggests targeting common pathways is better for intervention instead of individual gene mutations.
CTD2 researchers at UCSF-1 present a quantitative map linking the influence of chemotherapeutic agents to tumor genetics. This chemical-genetic interaction map can aid in identifying new factors that dictate responses to chemotherapy and prioritize drug combinations.
Scientists have developed a cancer dependency map by combining off-target effects of RNAi and genomic characterization information across 501 cancer cell lines. The map facilitates identification and prioritization of therapeutic targets by predicting the genes essential for cell viability.
Plasticity of the cell state is proposed to drive resistance to multiple classes of cancer therapies. CTD2 researchers characterized this therapy-resistant cell state in human cancer cells and identify vulnerability to ferroptosis by inhibition of a lipid peroxidase.
TARGET researchers perform the first comprehensive genomic study of T-lineage acute lymphoblastic leukemia (T-ALL) and identify a large number of unrecognized driver mutations in targetable pathways. These results have significant therapeutic weight in children with T-ALL.
CTD2 researchers at UTSW investigate alterations in oncogene-specific cellular signaling pathways in non-small cell lung cancer. BLC6 was identified as a target for combination therapy and may be potent way to overcome intratumor heterogeneity.